Roger Stupp

Roger Stupp's AcademicInfluence.com Rankings

Roger Stupp

Philosophy

#5638

World Rank

#8499

Historical Rank

Logic

#2874

World Rank

#3944

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Roger Stupp's Degrees

Doctorate Medicine University of Zurich
PhD Medicine University of Zurich

Why Is Roger Stupp Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Roger Stupp's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. (2005) (16695)
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. (2009) (6397)
MGMT gene silencing and benefit from temozolomide in glioblastoma. (2005) (4989)
Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. (2010) (2448)
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial (2017) (1217)
Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. (2012) (1019)
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. (2015) (910)
Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. (2002) (816)
Clinical Trial Substantiates the Predictive Value of O-6-Methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastoma Patients Treated with Temozolomide (2004) (773)
Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. (2013) (771)
Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. (2008) (747)
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. (2014) (744)
European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. (2017) (736)
Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. (2008) (682)
MGMT promoter methylation in malignant gliomas: ready for personalized medicine? (2010) (667)
NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. (2012) (650)
EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. (2014) (601)
Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. (2004) (582)
Lomustine and Bevacizumab in Progressive Glioblastoma (2017) (540)
High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2014) (507)
Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. (2008) (496)
cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV” (2018) (492)
Chemoradiotherapy in malignant glioma: standard of care and future directions. (2007) (484)
Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. (2006) (462)
Guidelines on management of low‐grade gliomas: report of an EFNS–EANO * Task Force (2010) (453)
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. (2017) (452)
Current concepts and management of glioblastoma (2011) (429)
Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial. (2003) (401)
Plasma and Cerebrospinal Fluid Population Pharmacokinetics of Temozolomide in Malignant Glioma Patients (2004) (396)
Changing paradigms--an update on the multidisciplinary management of malignant glioma. (2006) (394)
Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. (2001) (373)
Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (2016) (342)
Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. (2010) (338)
Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. (2007) (313)
Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. (2003) (301)
Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes. (2003) (293)
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma (2017) (291)
High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2010) (288)
Health-related quality of life in patients with glioblastoma: a randomised controlled trial. (2005) (287)
An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients. (2010) (282)
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma (2011) (273)
Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study (2017) (271)
Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial (2015) (269)
Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy. (2009) (258)
MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial (2015) (256)
cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas (2020) (253)
MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status (2012) (242)
Corticosteroids compromise survival in glioblastoma. (2016) (239)
Novel, improved grading system(s) for IDH-mutant astrocytic gliomas (2018) (236)
Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. (2010) (233)
Current and future developments in the use of temozolomide for the treatment of brain tumours. (2001) (230)
Phase II study of imatinib in advanced chordoma. (2012) (230)
Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. (2007) (230)
Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. (2008) (224)
Anti‐O6‐Methylguanine‐Methyltransferase (MGMT) Immunohistochemistry in Glioblastoma Multiforme: Observer Variability and Lack of Association with Patient Survival Impede Its Use as Clinical Biomarker * (2008) (223)
The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate (2004) (211)
Performance of 18F-Fluoro-Ethyl-Tyrosine (18F-FET) PET for the Differential Diagnosis of Primary Brain Tumor: A Systematic Review and Metaanalysis (2012) (209)
Temozolomide-Mediated Radiation Enhancement in Glioblastoma: A Report on Underlying Mechanisms (2006) (208)
Glioma (2015) (202)
Radiation recall: a well recognized but neglected phenomenon. (2005) (198)
Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice. (2012) (189)
Optimal role of temozolomide in the treatment of malignant gliomas (2005) (187)
Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study (2006) (185)
Molecular neuro-oncology in clinical practice: a new horizon. (2013) (182)
Proven bioequivalence of blood exposure between vinorelbine 80 mg/m2 oral and 30 mg/m2 IV doses in cancer patients (2005) (174)
Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer. (2002) (171)
New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials. (2012) (168)
A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy. (2005) (167)
Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. (2009) (162)
Molecular diagnostics of gliomas: the clinical perspective (2010) (153)
Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: A systematic review. (2017) (148)
MST4 Phosphorylation of ATG4B Regulates Autophagic Activity, Tumorigenicity, and Radioresistance in Glioblastoma (2017) (147)
Cilengitide: an integrin-targeting arginine–glycine–aspartic acid peptide with promising activity for glioblastoma multiforme (2008) (143)
Integrin inhibitors reaching the clinic. (2007) (141)
MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges. (2018) (134)
Maturation of tertiary lymphoid structures and recurrence of stage II and III colorectal cancer (2017) (133)
Minimal clinically meaningful differences for the EORTC QLQ-C30 and EORTC QLQ-BN20 scales in brain cancer patients. (2011) (132)
Optimal management of elderly patients with glioblastoma. (2013) (132)
Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma. (2016) (131)
Epidermal Growth Factor Receptor Inhibitors in Neuro-oncology: Hopes and Disappointments (2008) (125)
Epilepsy meets cancer: when, why, and what to do about it? (2012) (124)
Tumor treating fields: a novel treatment modality and its use in brain tumors (2016) (124)
IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma (2018) (122)
Infiltrating T Cells Increase IDO1 Expression in Glioblastoma and Contribute to Decreased Patient Survival (2017) (122)
The effect of Rituximab on patients with follicular and mantle-cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK). (2000) (120)
The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria (2014) (120)
RTOG 0525: A randomized phase III trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense (dd) schedule in newly diagnosed glioblastoma (GBM). (2011) (119)
Recent developments in the use of chemotherapy in brain tumours. (2006) (116)
Standards of care and novel approaches in the management of glioblastoma multiforme (2014) (116)
Bevacizumab and recurrent malignant gliomas: a European perspective. (2010) (115)
Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients. (2006) (115)
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial (2018) (114)
Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. (2016) (114)
The Role of Radio- and Chemotherapy in Glioblastoma (2005) (111)
Are Integrins Still Practicable Targets for Anti-Cancer Therapy? (2019) (108)
Modulation of Angiogenic and Inflammatory Response in Glioblastoma by Hypoxia (2009) (104)
Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG (2015) (104)
The prognostic value of health-related quality-of-life data in predicting survival in glioblastoma cancer patients: results from an international randomised phase III EORTC Brain Tumour and Radiation Oncology Groups, and NCIC Clinical Trials Group study (2007) (101)
Effect of computerisation on the quality and safety of chemotherapy prescription (2006) (101)
Targeting integrins in malignant glioma (2010) (100)
Anaplastic astrocytoma in adults. (2007) (99)
CAR T-Cell Therapies in Glioblastoma: A First Look (2017) (97)
Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082) (2016) (97)
New validated prognostic models and prognostic calculators in patients with low-grade gliomas diagnosed by central pathology review: a pooled analysis of EORTC/RTOG/NCCTG phase III clinical trials. (2013) (96)
Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trial. (2009) (94)
Combined modality therapy of head and neck cancer. (1994) (94)
The Wnt inhibitory factor 1 (WIF1) is targeted in glioblastoma and has a tumor suppressing function potentially by induction of senescence. (2011) (93)
Small cell lung cancer: state of the art and future perspectives. (2004) (93)
Cilengitide: an RGD pentapeptide ανβ3 and ανβ5 integrin inhibitor in development for glioblastoma and other malignancies. (2011) (92)
LB-05PHASE III TRIAL EXPLORING THE COMBINATION OF BEVACIZUMAB AND LOMUSTINE IN PATIENTS WITH FIRST RECURRENCE OF A GLIOBLASTOMA: THE EORTC 26101 TRIAL (2015) (91)
Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro. (2009) (90)
The accuracy of predicting survival in individual patients with cancer. (2014) (89)
A novel tool to analyze MRI recurrence patterns in glioblastoma. (2008) (87)
ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016 (2016) (86)
Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme. (2008) (86)
Elevated levels of MIC‐1/GDF15 in the cerebrospinal fluid of patients are associated with glioblastoma and worse outcome (2009) (85)
Epilepsy in brain tumor patients. (2010) (83)
Malignant glioma: ESMO clinical recommendations for diagnosis, treatment and follow-up. (2007) (82)
Extent and Patterns of MGMT Promoter Methylation in Glioblastoma- and Respective Glioblastoma-Derived Spheres (2010) (82)
EORTC study 26041-22041: phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma. (2010) (80)
Newly Diagnosed Glioblastoma: A Review on Clinical Management. (2019) (79)
Temozolomide: a milestone in neuro-oncology and beyond? (2006) (79)
Concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM). Conclusive results of a randomized phase III trial by the EORTC Brain & RT Groups and NCIC Clinical Trials Group (2004) (78)
Targeting brain-tumor stem cells (2007) (78)
Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial (2012) (78)
Chromosome 7 gain and DNA hypermethylation at the HOXA10 locus are associated with expression of a stem cell related HOX-signature in glioblastoma (2015) (77)
Individualized Targeted Therapy for Glioblastoma: Fact or Fiction? (2012) (77)
Biological activity of tumor-treating fields in preclinical glioma models (2017) (75)
MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials (2018) (74)
Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck. (1998) (71)
Levetiracetam and pregabalin for antiepileptic monotherapy in patients with primary brain tumors. A phase II randomized study. (2014) (70)
Withholding temozolomide in glioblastoma patients with unmethylated MGMT promoter--still a dilemma? (2015) (68)
Molecular-Based Recursive Partitioning Analysis Model for Glioblastoma in the Temozolomide Era: A Correlative Analysis Based on NRG Oncology RTOG 0525 (2017) (67)
Non steroidal anti‐inflammatory drugs and COX‐2 inhibitors as anti‐cancer therapeutics: hypes, hopes and reality (2003) (67)
Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study. (2005) (65)
The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033 (2018) (64)
EORTC 26101 phase III trial exploring the combination of bevacizumab and lomustine in patients with first progression of a glioblastoma. (2016) (63)
Malignant glioma: ESMO clinical recommendations for diagnosis, treatment and follow-up. (2008) (62)
Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome (2016) (61)
Epigenetic Deregulation of DNA Repair and Its Potential for Therapy (2009) (59)
NT-40Interim Analysis of the EF-14 Trial: A Prospective, Multi-center Trial of NovoTTF-100A Together With Temozolomide Compared to Temozolomide Alone in Patients with Newly Diagnosed GBM (2014) (59)
Prognostic factors for low-grade gliomas. (2003) (58)
Docetaxel-cisplatin-5FU (TCF) versus docetaxel-cisplatin (TC) versus epirubicin-cisplatin-5FU (ECF) as systemic treatment for advanced gastric carcinoma (AGC): A randomized phase II trial of the Swiss Group for Clinical Cancer Research (SAKK). (2004) (58)
ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of malignant glioma. (2005) (57)
Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression (2014) (54)
EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma. (2012) (54)
Glioblastoma (GBM) in elderly patients: A randomized phase III trial comparing survival in patients treated with 6-week radiotherapy (RT) versus hypofractionated RT over 2 weeks versus temozolomide single-agent chemotherapy (TMZ). (2010) (54)
Tenascin‐W, a new marker of cancer stroma, is elevated in sera of colon and breast cancer patients (2008) (53)
ATIM-03. ACT IV: AN INTERNATIONAL, DOUBLE-BLIND, PHASE 3 TRIAL OF RINDOPEPIMUT IN NEWLY DIAGNOSED, EGFRvIII-EXPRESSING GLIOBLASTOMA (2016) (50)
Methylguanine methyltransferase testing in glioblastoma: when and how? (2007) (50)
The level of patient-reported outcome reporting in randomised controlled trials of brain tumour patients: a systematic review. (2014) (49)
MGMT Methylation Status: The Advent of Stratified Therapy in Glioblastoma? (2007) (48)
Pregabalin in patients with primary brain tumors and seizures: A preliminary observation (2009) (47)
Ultrasound-mediated Delivery of Paclitaxel for Glioma: A Comparative Study of Distribution, Toxicity, and Efficacy of Albumin-bound Versus Cremophor Formulations (2019) (47)
Cost‐effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme (2008) (46)
Temozolomide chemotherapy versus radiotherapy in molecularly characterized (1p loss) low-grade glioma: A randomized phase III intergroup study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-26033). (2013) (46)
Adjuvant dibromodulcitol and BCNU chemotherapy in anaplastic astrocytoma: results of a randomised European Organisation for Research and Treatment of Cancer phase III study (EORTC study 26882). (2008) (46)
Bevacizumab for recurrent ependymoma (2009) (46)
5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere)-cisplatin in advanced gastric carcinoma: a phase I-II trial. (2004) (46)
Phase I/IIa trial of cilengitide (EMD121974) and temozolomide with concomitant radiotherapy, followed by temozolomide and cilengitide maintenance therapy in patients (pts) with newly diagnosed glioblastoma (GBM) (2007) (45)
Multicentre phase II and pharmacokinetic study of RFS2000 (9-nitro-camptothecin) administered orally 5 days a week in patients with glioblastoma multiforme. (2002) (44)
Listeria brain abscess, Pneumocystis pneumonia and Kaposi's sarcoma after temozolomide (2006) (44)
Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03. (2008) (43)
The quest for surrogate markers of angiogenesis: a paradigm for translational research in tumor angiogenesis and anti-angiogenesis trials. (2003) (43)
European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme. (2003) (41)
Monitoring multiple angiogenesis‐related molecules in the blood of cancer patients shows a correlation between VEGF‐A and MMP‐9 levels before treatment and divergent changes after surgical vs. conservative therapy (2006) (40)
New trends in the medical management of glioblastoma multiforme: the role of temozolomide chemotherapy. (2006) (40)
Concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM). Conclusive results of a randomized phase III trial by the EORTC Brain & RT Groups and NCIC Clinical Trials Group. (2004) (40)
Health-related quality of life in small-cell lung cancer: a systematic review on reporting of methods and clinical issues in randomised controlled trials. (2014) (40)
European perspective for effective cancer drug development (2014) (40)
Comparison of neoadjuvant cisplatin-based chemotherapy versus radiochemotherapy followed by resection for stage III (N2) NSCLC. (2005) (40)
Perfusion and diffusion MRI of glioblastoma progression in a four-year prospective temozolomide clinical trial. (2006) (39)
Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group (2011) (39)
Aberrant Lck Signal via CD28 Costimulation Augments Antigen-Specific Functionality and Tumor Control by Redirected T Cells with PD-1 Blockade in Humanized Mice (2018) (38)
Preoperative versus postoperative docetaxel-cisplatin-fluorouracil (TCF) chemotherapy in locally advanced resectable gastric carcinoma: 10-year follow-up of the SAKK 43/99 phase III trial. (2016) (37)
Prolonged survival for patients with newly diagnosed, inoperable glioblastoma with 3-times daily ultrafractionated radiation therapy. (2010) (36)
A phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumours. (2013) (36)
Frequently asked questions in the medical management of high-grade glioma: a short guide with practical answers. (2008) (36)
Cost of temozolomide therapy and global care for recurrent malignant gliomas followed until death. (2005) (36)
Combination of MRI and dynamic FET PET for initial glioma grading (2014) (35)
Quality assurance of the EORTC 26981/22981; NCIC CE3 intergroup trial on radiotherapy with or without temozolomide for newly-diagnosed glioblastoma multiforme: the individual case review. (2004) (35)
Use of metformin and outcome of patients with newly diagnosed glioblastoma: Pooled analysis (2020) (34)
Proangiogenic factor PlGF programs CD11b(+) myelomonocytes in breast cancer during differentiation of their hematopoietic progenitors. (2011) (34)
Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial. (2021) (34)
Acute tubulo-interstitial nephritis with uveitis (TINU Syndrome) in a patient with serologic evidence for Chlamydia infection (1990) (34)
Extensive brainstem infiltration, not mass effect, is a common feature of end-stage cerebral glioblastomas. (2019) (34)
Evaluation of oral versus intravenous dose of vinorelbine to achieve equivalent blood exposures in patients with solid tumours (2007) (33)
Cost–effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme (2009) (33)
Can we afford to add chemotherapy to radiotherapy for glioblastoma multiforme? Cost‐identification analysis of concomitant and adjuvant treatment with temozolomide until patient death (2004) (32)
Tumor treating fields (TTFields): A novel treatment modality added to standard chemo- and radiotherapy in newly diagnosed glioblastoma—First report of the full dataset of the EF14 randomized phase III trial. (2015) (32)
Quality assurance in the EORTC 22033-26033/CE5 phase III randomized trial for low grade glioma: the digital individual case review. (2012) (31)
Primary Central Nervous System Lymphoma-PART 1: Epidemiology, Diagnosis, Staging, and Prognosis. (2018) (30)
Brain tumors: molecular biology and targeted therapies. (2006) (30)
Will integrin inhibitors have proangiogenic effects in the clinic? (2009) (29)
A prospective, randomized, open-label, phase III clinical trial of NovoTTF-100A versus best standard of care chemotherapy in patients with recurrent glioblastoma. (2010) (28)
Low-grade glioma: a challenge in therapeutic options: the role of radiotherapy. (2008) (28)
PRMT6 methylation of RCC1 regulates mitosis, tumorigenicity, and radiation response of glioblastoma stem cells. (2021) (28)
Activation of 4-1BBL+ B cells with CD40 agonism and IFNγ elicits potent immunity against glioblastoma (2020) (28)
A phase 1b study of humanized KS-interleukin-2 (huKS-IL2) immunocytokine with cyclophosphamide in patients with EpCAM-positive advanced solid tumors (2013) (28)
Structural and functional reorganization of propriospinal connections promotes functional recovery after spinal cord injury (2017) (28)
Irinotecan-induced interstitial pneumonia. (2004) (27)
Clinical Implications of Molecular Neuropathology and Biomarkers for Malignant Glioma (2012) (27)
Symptom clusters in newly diagnosed glioma patients: which symptom clusters are independently associated with functioning and global health status? (2019) (27)
T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein (2013) (27)
Do statins, ACE inhibitors or sartans improve outcome in primary glioblastoma? (2018) (27)
Individual versus standard quality of life assessment in a phase II clinical trial in mesothelioma patients: feasibility and responsiveness to clinical changes. (2008) (26)
The dream and reality of histology agnostic cancer clinical trials (2014) (26)
Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement. (2021) (26)
Cilengitide in newly diagnosed glioblastoma with MGMT promoter methylation: Protocol of a multicenter, randomized, open-label, controlled phase III trial (CENTRIC). (2010) (26)
Personalised medicine in oncology: questions for the next 20 years. (2012) (25)
CPT-11 and concomitant hyperfractionated accelerated radiotherapy induce efficient local control in rectal cancer patients: results from a phase II (2006) (25)
Should biomarkers be used to design personalized medicine for the treatment of glioblastoma? (2010) (25)
New approaches for temozolomide therapy: use in newly diagnosed glioma. (2001) (25)
Ventricular arrhythmia and torsade de pointe: dose limiting toxicities of the MDR-modulator S9788 in a phase I trial. (1998) (25)
The role of paclitaxel in the treatment of head and neck cancer. (1995) (24)
Treatment of Primary CNS Lymphoma (2013) (24)
Improving survival in molecularly selected glioblastoma (2019) (24)
Ipilimumab and early signs of pulmonary toxicity in patients with metastastic melanoma: a prospective observational study (2017) (23)
Appropriate end-points for right results in the age of antiangiogenic agents: future options for phase II trials in patients with recurrent glioblastoma. (2012) (23)
Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial. (2018) (23)
Erratum to: MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status (2013) (23)
Is Long-Term Survival in Glioblastoma Possible? Updated Results of the EORTC/NCIC Phase III Randomized Trial on Radiotherapy (RT) and Concomitant and Adjuvant Temozolomide (TMZ) versus RT Alone (2007) (23)
The role of integrins in glioma biology and anti-glioma therapies. (2011) (22)
Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II study (2018) (22)
Preoperative hyperfractionated accelerated radiotherapy (HART) and concomitant CPT-11 in locally advanced rectal carcinoma: a phase I study. (2001) (22)
Phase II study of docetaxel in the treatment of patients with advanced non-small cell lung cancer in routine daily practice. (2000) (22)
Imaging tryptophan uptake with positron emission tomography in glioblastoma patients treated with indoximod (2018) (22)
Medulloblastomas in adults: prognostic factors and lessons from paediatrics. (2011) (21)
Leptomeningeal metastasis from solid tumors (2020) (21)
LTBK-01: PROSPECTIVE, MULTI-CENTER PHASE III TRIAL OF TUMOR TREATING FIELDS TOGETHER WITH TEMOZOLOMIDE COMPARED TO TEMOZOLOMIDE ALONE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (2016) (21)
Neuro-oncology, a decade of temozolomide and beyond (2010) (21)
A phase 0 first-in-human study using NU-0129: A gold base spherical nucleic acid (SNA) nanoconjugate targeting BCL2L12 in recurrent glioblastoma patients. (2019) (21)
Dummy run and conformity indices in the ongoing EORTC low-grade glioma trial 22033-26033: First evaluation of quality of radiotherapy planning. (2010) (21)
Clinical management and outcome of histologically verified adult brainstem gliomas in Switzerland: a retrospective analysis of 21 patients (2014) (21)
Concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM). Conclusive results of a randomized phase III trial by the EORTC (2005) (21)
Brain metastasis: opportunity for drug development? (2012) (21)
The added value of health-related quality of life as a prognostic indicator of overall survival and progression-free survival in glioma patients: a meta-analysis based on individual patient data from randomised controlled trials. (2019) (20)
Promises and controversies in the management of low-grade glioma. (2003) (20)
Molecular imaging in the development of a novel treatment paradigm for glioblastoma (GBM): an integrated multidisciplinary commentary. (2013) (19)
Multicentre phase II study of imatinib mesylate in patients with recurrent anaplastic oligodendroglioma (AOD)/mixed oligoastrocytoma (MOA) and anaplastic astrocytoma (AA)/low grade astrocytoma (LGA): An EORTC New Drug Development Group (NDDG) and Brain Tumor Group (BTG) study (2005) (19)
Neoadjuvant chemotherapy with or without preoperative irradiation in stage IIIA/N2 non-small cell lung cancer (NSCLC): A randomized phase III trial by the Swiss Group for Clinical Cancer Research (SAKK trial 16/00). (2013) (19)
One and a half decades of the Lugano International Conference on Malignant Lymphoma: variations on a theme or true progress? (1997) (19)
Current and Future Trials of the EORTC Brain Tumor Group (2004) (19)
Deep-learning-based synthesis of post-contrast T1-weighted MRI for tumour response assessment in neuro-oncology: a multicentre, retrospective cohort study. (2021) (17)
Genome-wide DNA methylation detection by MethylCap-seq and Infinium HumanMethylation450 BeadChips: an independent large-scale comparison (2015) (17)
Is there a place for radiotherapy in low-grade gliomas? (2010) (17)
Development of OXY111A, a novel hypoxia-modifier as a potential antitumor agent in patients with hepato-pancreato-biliary neoplasms - Protocol of a first Ib/IIa clinical trial (2016) (17)
Cytostatic lung perfusion results in heterogeneous spatial regional blood flow and drug distribution: evaluation of different cytostatic lung perfusion techniques in a porcine model. (2006) (17)
DDRE-14. DE-NOVO PURINE BIOSYNTHESIS IS A MAJOR DRIVER OF CHEMORESISTANCE IN GLIOBLASTOMA (2020) (17)
Temporal activation of WNT/β-catenin signaling is sufficient to inhibit SOX10 expression and block melanoma growth (2020) (16)
Hydroxyurea with continuous infusion paclitaxel, 5-fluorouracil, and concomitant radiotherapy for poor-prognosis head and neck cancer. (1995) (16)
Diagnostic value of 18F-fluordesoxyglucose positron emission tomography for patients with brain metastasis from unknown primary site. (2018) (16)
Impact of Radiation Target Volume on Health-Related Quality of Life in Patients With Low-Grade Glioma in the 2-Year Period Post Treatment: A Secondary Analysis of the EORTC 22033-26033. (2019) (16)
Bevacizumab for recurrent ependymoma. (2009) (16)
ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma (2021) (16)
Does cilengitide deserve another chance?-Authors' reply. (2014) (15)
Determining the Optimal Adjuvant Therapy for Improving Survival in Elderly Patients with Glioblastoma: A Systematic Review and Network Meta-analysis (2020) (15)
Questions regarding the optimal use of bevacizumab in glioblastoma: a moving target. (2014) (15)
Decision making and management of gliomas: practical considerations. (2012) (15)
Ribosomal protein S11 influences glioma response to TOP2 poisons (2020) (15)
Phase II part of EORTC study 26101: The sequence of bevacizumab and lomustine in patients with first recurrence of a glioblastoma. (2016) (14)
Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long‐Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01) (2019) (14)
New drugs and combinations for malignant glioma. (2003) (14)
Efficacy of vinorelbine plus granulocyte colony-stimulation factor for CD34+ hematopoietic progenitor cell mobilization in patients with multiple myeloma. (2015) (14)
PROX1 is a novel pathway-specific prognostic biomarker for high-grade astrocytomas; results from independent glioblastoma cohorts stratified by age and IDH mutation status (2016) (14)
Overcoming the Blood–Brain Barrier with an Implantable Ultrasound Device (2019) (14)
Memory in low-grade glioma patients treated with radiotherapy or temozolomide: a correlative analysis of EORTC study 22033-26033 (2020) (13)
The Neurologic Assessment in Neuro-Oncology (NANO) Scale: A Tool to Assess Neurologic Function for Integration in the Radiologic Assessment in Neuro-Oncology (RANO) Criteria (S22.005) (2014) (13)
Malignant glioma: ESMO clinical recommendations for diagnosis, treatment and follow-up. (2008) (12)
Primetime for antiangiogenic therapy (2009) (12)
Abstract CT007: Tumor treating fields added to standard chemotherapy in newly diagnosed glioblastoma (GBM): Final results of a randomized, multi-center, phase III trial (2017) (12)
Valproic acid related idiosyncratic drug induced hepatotoxicity in a glioblastoma patient treated with temozolomide. (2008) (12)
Is Cisplatin Required for the Treatment of Non-Small-Cell Lung Cancer? Experience and Preliminary Results of a Phase I/II Trial with Topotecan and Vinorelbine (2000) (12)
Accelerated postoperative radiotherapy with weekly concomitant boost in patients with locally advanced head and neck cancer. (2004) (12)
APG101_CD_002: A phase II, randomized, open-label, multicenter study of weekly APG101 plus reirradiation versus reirradiation in the treatment of patients with recurrent glioblastoma. (2012) (11)
18F-fluorodeoxyglucose PET/CT findings in pleural effusions of patients with known cancer (2012) (11)
Treatment strategies and outcome of surgery for synchronous colorectal liver metastases. (2017) (11)
Brain cancer in 2012: Molecular characterization leads the way (2013) (11)
5FU as protracted continuous IV infusion (5FUpiv) can be added to full dose taxotere-cisplatin (TC) in advanced gastric carcinoma (AGC) (1999) (11)
Temporal Muscle Thickness as a Prognostic Marker in Patients with Newly Diagnosed Glioblastoma: Translational Imaging Analysis of the CENTRIC EORTC 26071–22072 and CORE Trials (2021) (11)
1195OFINAL RESULTS OF THE SAKK 16/00 TRIAL: A RANDOMIZED PHASE III TRIAL COMPARING NEOADJUVANT CHEMORADIATION TO CHEMOTHERAPY ALONE IN STAGE IIIA/N2 NON-SMALL CELL LUNG CANCER (NSCLC). (2014) (10)
Methylome analyses of three glioblastoma cohorts reveal chemotherapy sensitivity markers within DDR genes (2020) (10)
Combined modality treatment with full-dose chemotherapy and concomitant boost radiotherapy for advanced head and neck carcinoma (2003) (10)
Antegrade versus retrograde isolated lung perfusion: doxorubicin uptake and distribution in a sarcoma model. (2006) (10)
Corrigendum to “Comparison of neoadjuvant cisplatin-based chemotherapy versus radiochemotherapy followed by resection for stage III (N2) NSCLC” [Eur J Cardiothorac Surg 27 (2005) 1092–1098] (2005) (10)
Drug development for glioma: are we repeating the same mistakes? (2019) (10)
Associations of anticoagulant use with outcome in newly diagnosed glioblastoma. (2018) (10)
EORTC Study 26041–22041: Phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with or without PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma—Results of a phase I trial (2007) (10)
Role of Resection in Glioblastoma Management. (2021) (10)
[A practical guide for the management of gliomas]. (2007) (10)
World Congress Integrative Medicine & Health 2017: part two (2017) (9)
Ongoing clinical trials. (2003) (9)
Malignant astrocytoma in elderly patients: where do we stand? (2013) (9)
C3-07: Preoperative chemoradiotherapy followed by surgery for stage IIIB non-small cell lung cancer (NSCLC). A multicenter phase II trial of the Swiss Group for Clinical Cancer Research (SAKK) (2007) (9)
Addition of lomustine for bevacizumab-refractory recurrent glioblastoma (2014) (9)
Radiotherapy in low-grade gliomas: Cons. (2003) (9)
A phase 1, multicenter, open-label study of marizomib (MRZ) with temozolomide (TMZ) and radiotherapy (RT) in newly diagnosed WHO grade IV malignant glioma (glioblastoma, ndGBM): Dose-escalation results. (2018) (9)
Efficacy of vinorelbine plus G-CSF for CD34+ hematopoietic progenitor cell mobilization in patients with multiple myeloma (2015) (9)
A phase I pharmacokinetic study of hypoxic abdominal stop-flow perfusion with gemcitabine in patients with advanced pancreatic cancer and refractory malignant ascites (2008) (9)
Efficacious and save use of biosimilar filgrastim for hematopoietic progenitor cell chemo‐mobilization with vinorelbine in multiple myeloma patients (2017) (9)
Radiotherapy in relation to temozolomide: Subgroup analysis of molecular markers of the randomized phase III study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-26033) in patients with a high risk low-grade glioma. (2015) (9)
Management of Malignant Glioma – Quo Vadis? (2008) (9)
Neoadjuvant chemotherapy followed by extrapleural pneumonectomy for malignant pleural mesothelioma (MPM): A multicenter phase II trial of the SAKK. (2004) (9)
Neuro-oncology: In search of molecular markers of glioma in elderly patients (2013) (9)
[Therapeutic strategies for the management of gliomas]. (2008) (8)
5-fluorouracil plus radiation for head and neck cancer. (1995) (8)
The Impact of Tumor Treating Fields on Glioblastoma Progression Patterns. (2021) (8)
Correlative studies in neuro-oncology trials: Should they influence treatment? (2006) (8)
Tumor Treating Fields (TTFields)—A Novel Cancer Treatment Modality: Translating Preclinical Evidence and Engineering Into a Survival Benefit with Delayed Decline in Quality of Life. (2017) (7)
Micropapillary pattern in lung adenocarcinoma: aspect on 18F-fluorodeoxyglucose positron emission tomography/computed tomography imaging. (2010) (7)
Establishing anchor-based minimally important differences for the EORTC QLQ-C30 in glioma patients (2021) (7)
Full enrollment results from an extended phase I, multicenter, open label study of marizomib (MRZ) with temozolomide (TMZ) and radiotherapy (RT) in newly diagnosed glioblastoma (GBM). (2019) (7)
Cancer clinical trials--do we need a new algorithm in the age of stratified medicine? (2013) (7)
Developing an Integrative Treatment Program for Cancer-Related Fatigue Using Stakeholder Engagement – A Qualitative Study (2017) (7)
Radiotherapy with Concurrent and Adjuvant Temozolomide: A New Standard of Care for Glioblastoma Multiforme (2006) (7)
83 Phase II study of docetaxel (Taxotere®) in locally advanced or metastatic non-small cell lung cancer (NSCLC): Interim report on 204 patients (1997) (7)
Primary Central Nervous System Lymphoma-PART 2: Modern Therapeutic Management and Future Directions. (2018) (7)
Treatment for Patients With Newly Diagnosed Glioblastoma--Reply. (2016) (7)
Phase II trial of the epothilone analog sagopilone (ZK219477; ZK EPO) in patients with recurrent glioblastoma: Initial report of the EORTC study 26061 (2008) (7)
Phase II study of docetaxel alternating with cisplatin in chemotherapy-naïve patients with advanced non-small cell lung cancer (2000) (6)
Clinical prognostic factors affecting survival in patients with newly diagnosed Glioblastoma Multiforme (GBM). (2004) (6)
Preoperative chemoradiotherapy with cisplatin and docetaxel for stage IIIB non-small-cell lung cancer: 10-year follow-up of the SAKK 16/01 trial. (2016) (6)
Informed consent: true information or institutional review board-approved disinformation? (2007) (6)
The EORTC QLQ-BN20 questionnaire for assessing the health-related quality of life (HRQoL) in brain cancer patients: A phase IV validation study on behalf of the EORTC QLG, BCG, ROG, NCIC-CTG (2008) (6)
Trimodality therapy for locally advanced non-small-cell lung cancer: a curative approach. (2011) (6)
31 Temozolomide (TMZ) targets only glioblastoma with a silenced MGMT-gene. Results of a translational companion study to EORTC 26981/NCIC CE.3 of radiotherapy ± TMZ (2004) (6)
Approval of new drugs for glioblastoma. (2009) (6)
Weekly x 4 induction therapy with the anti-CD20 antibody rituximab: effect on circulating t(14;18)(+) follicular lymphoma cells. (2001) (6)
2010: neuro-oncology is moving! (2010) (6)
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation: Final results of the multicenter, randomized, open-label, controlled, phase III CENTRIC study. (2013) (5)
Chiasmatic Infiltration Secondary to Late Malignant Transformation of Retinoma (2012) (5)
Diagnostic value of 18 F-fluordesoxyglucose positron emission tomography for patients with brain metastasis from unknown primary site (2018) (5)
B cell-rich non-neoplastic sentinel lesion preceding primary central nervous system lymphoma (2018) (5)
An open-label, phase I study of cetuximab to assess the safety, efficacy and pharmacokinetics (PK) of different cetuximab regimens in patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC). (2005) (5)
ATCT-35QUALITY OF LIFE, COGNITIVE FUNCTION AND FUNCTIONAL STATUS IN THE EF-14 TRIAL: A PROSPECTIVE, MULTI-CENTER TRIAL OF TTFIELDS WITH TEMOZOLOMIDE COMPARED TO TEMOZOLOMIDE ALONE IN PATIENTS WITH NEWLY DIAGNOSED GBM (2015) (5)
Quality of Life in Patients With Glioblastoma Treated With Tumor-Treating Fields-Reply. (2018) (5)
[Role of MGMT and clinical applications in brain tumours]. (2007) (5)
Predicting survival using health related quality of life scores in glioblastoma cancers: Findings from an international phase III randomised controlled trial (2005) (5)
Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small cell lung cancer (NSCLC): Preliminary results. A study of the Swiss Group for Clinical Cancer Research (SAKK) (2005) (5)
Mobilization of Hematopoietic Progenitor Cells with Standard- or Reduced-Dose Filgrastim after Vinorelbine in Multiple Myeloma Patients: A Randomized Prospective Single-Center Phase II Study. (2017) (5)
[Advances in the treatment of head and neck tumors. 2. Radiochemotherapy]. (1995) (4)
Evidence-based management of adult patients with diffuse glioma - Authors' reply. (2017) (4)
Go, no-go decision making for phase 3 clinical trials: ACT IV revisited - Authors' reply. (2017) (4)
MGMT promoter methylation is associated with patient age and 1p/19q status in IDH-mutant gliomas. (2021) (4)
PET Imaging in Glioma: The Neuro-Oncologist's Expectations. (2013) (4)
RTOG 0525: Exploratory Subset Analysis from a Randomized Phase III Trial Comparing Standard (std) Adjuvant Temozolomide (TMZ) with a Dose-dense (dd) Schedule for Glioblastoma (GBM) (2011) (4)
Prognostic significance of therapy-induced myelosuppression in newly diagnosed glioblastoma. (2022) (4)
NEURO/MEDICAL ONCOLOGY (2013) (4)
CORRELATION OF ENZYME-INDUCING ANTICONVULSANT USE WITH OUTCOME OF PATIENTS WITH GLIOBLASTOMA (2010) (4)
CSIG-35. MST4 PHOSPHORYLATION OF ATG4B REGULATES AUTOPHAGIC ACTIVITY, TUMORIGENICITY, AND RADIORESISTANCE IN GLIOBLASTOMA (2018) (4)
Neuro-oncology: oligodendroglioma and molecular markers (2007) (4)
Guidelines on the Management of Low-grade Gliomas: EANO Task Force Report (2012) (4)
Interim results of a phase II study of docetaxel (Taxotere™) in unresectable non-small cell lung cancer (NSCLC) on 204 chemotherapy naive or pretreated patients (1997) (3)
Current Standards of Care in Glioblastoma Therapy (2016) (3)
The impact of the molecular classification of glioblastoma on the interpretation of therapeutic clinical trial results. (2021) (3)
ACTR-36. A PHASE I STUDY OF NEURAL STEM CELLS LOADED WITH AN ONCOLYTIC ADENOVIRUS FOR PATIENTS WITH NEWLY DIAGNOSED MALIGNANT GLIOMA: PRELIMINARY SAFETY AND DATA ANALYSIS (2017) (3)
The changing world of drug development: an academic research organization's perspective on the "Seven Wonders" of the future world of anticancer drug development. (2014) (3)
Leptomeningeal tumor response to combined MAPK/ERK inhibition in V600E-mutated gliomas despite undetectable CSF drug levels. (2019) (3)
Efficacy of clobazam as add-on therapy in brain tumor-related epilepsy (2021) (3)
Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials (2022) (3)
A Phase 1 b Study of Humanized Ks-Interleukin-2 ( Huks-Il 2 ) Immunocytokine with Cyclophosphamide in Patients with Epcam-Positive Advanced Solid Tumors (2018) (3)
DNA methylation-based age acceleration observed in IDH wild-type glioblastoma is associated with better outcome—including in elderly patients (2022) (3)
26LBA Does valproic acid improve survival in glioblastoma? A meta-analysis of randomized trials in newly diagnosed glioblastoma (2015) (3)
Measuring change in health-related quality of life: the impact of different analytical methods on the interpretation of treatment effects in glioma patients (2020) (3)
A phase I/IIa study to evaluate the safety and efficacy of blood-brain barrier (BBB) opening with the SonoCloud-9 implantable ultrasound device in recurrent glioblastoma patients receiving IV carboplatin. (2021) (3)
CN2 COST-EFFECTIVENESS OFTEMOZOLOMIDE FORTHE TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME IN THE UK (2005) (2)
Current status of the preclinical evaluation of alternating electric fields as a form of cancer therapy. (2022) (2)
Leptomeningeal metastases: the future is now (2022) (2)
MEMORY FUNCTIONING IN LOW-GRADE GLIOMA PATIENTS TREATED WITH EITHER RADIOTHERAPY (RT) OR TEMOZOLOMIDE (TMZ) CHEMOTHERAPY. A CORRELATIVE ANALYSIS OF EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT (EORTC) STUDY 22033-26033 (2017) (2)
EORTC topics in neurooncology: The long path from a focus on neurological complications of cancer towards molecularly defined trials and therapies in neurooncology (2012) (2)
Atnt-10Does Valproic Acid Improve Survival In Glioblastoma? A Meta-Analysis Of Randomized Trials In Newly Diagnosed Glioblastoma (2015) (2)
[Advances in the treatment of head and neck tumors. I. Chemotherapy]. (1995) (2)
MGMT methylation testing in RTOG 0525: A phase III trial of newly diagnosed glioblastoma. (2009) (2)
Topotecan and vinorelbine is as effective, but less toxic than platinum-containing regimens against NSCLC. Promising results of this outpatient regimen in a phase I/II trial (2000) (2)
OS07.9 Standard of care temozolomide chemotherapy ± tumor treating fields (TTFields) in newly diagnosed glioblastoma. Final results of the phase III EF-14 clinical trial (2017) (2)
Ultrasound-mediated blood–brain barrier opening increases cell-free DNA in a time-dependent manner (2021) (2)
O-200 Neoadjuvant chemotherapy followed by pleuropneumonectomy for pleural mesothelioma: a multicenter phase II trial of the SAKK (2003) (2)
Recent developments in the management of maligant glioma. (2003) (2)
Prime time for molecular marker diagnostics in neuro-oncology. (2012) (2)
Little to learn from phase II trials in small-cell lung cancer. (1999) (2)
Reply to F. Felix et al and M.F. Fay et al. (2016) (1)
Development of OXY111A, a novel hypoxia-modifier as a potential antitumor agent in patients with hepato-pancreato-biliary neoplasms - Protocol of a first Ib/IIa clinical trial (2016) (1)
Reply to M.C. Chamberlain. (2014) (1)
[Prospective study of accelerated postoperative radiation therapy in patients with squamous-cell carcinoma of the head and neck]. (2003) (1)
Head and Neck Tumors (2003) (1)
ACTR-40. A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF MARIZOMIB (MRZ) WITH TEMOZOLOMIDE (TMZ) AND RADIOTHERAPY (RT) IN NEWLY DIAGNOSED WHO GRADE IV MALIGNANT GLIOMA (GLIOBLASTOMA, ndGBM): FULL ENROLLMENT RESULTS (2018) (1)
Repeated blood-brain barrier opening with an implantable ultrasound device for delivery of albumin-bound paclitaxel in patients with recurrent glioblastoma: a phase 1 trial. (2023) (1)
381 Repeated Opening of the Blood-Brain Barrier With the Skull-implantable SonoCloud-9 (SC9) Device: Phase 1 Trial of Nab-Paclitaxel and SC9 in Recurrent Glioblastoma (2022) (1)
Translocon-associated protein subunit SSR3 determines and predicts susceptibility to paclitaxel in breast cancer and glioblastoma. (2022) (1)
The Lugano International Conferences on Malignant Lymphoma, 1981-1993. (1994) (1)
943 Early administration of hemoglobin-adapted doses of erythropoletin with intravenous iron for the prevention of chemotherapy-induced anemia (2003) (1)
Abstract A110: EGFRvIII expression is associated with shorter progression-free and overall survival in glioblastoma patients treated with standard-of-care temozolomide and radiation: A report from the RTOG-0525 trial. (2013) (1)
Abstract 1504: Tumor-treating fields (TTFields) interfere with biological key properties of glioma cells in vitro (2017) (1)
WHO Guidelines for Diagnosis of Glial Tumours : What Is Old and What Is New ? (2011) (1)
Phase IB trial of EMD 273066 (huKS-IL2) with cyclophosphamide in patients with EpCAM-positive advanced solid tumors. (2011) (1)
Glioma immunoediting, a driver of tumor evolution, and the next battle for immunotherapy (2021) (1)
Hospital volume and group expertise in newly diagnosed glioblastoma management (2017) (1)
Omics and Prognostic Markers (2010) (1)
Publisher Correction: ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma (2022) (1)
Book Review Diseases of the Head and Neck, Nose and Throat Edited by Andrew S. Jones, David E. Phillips, and Frans J.M. Hilgers. 932 pp., illustrated. London, Arnold, 1998. (Distributed by Oxford University Press, New York.) $198.50. 0-340-64610-1 (1998) (1)
Intensified and accelerated concomitant chemoradiotherapy and G-CSF for locally advanced head and neck cancer (1993) (1)
Book Review Lung Cancer: Principles and Practice Second edition. Edited by Harvey I. Pass, James B. Mitchell, David H. Johnson, Andrew T. Turrisi, and John D. Minna. 1177 pp., illustrated. Philadelphia, Lippincott Williams & Wilkins, 2000. $169. 0-7817-1791-4 (2001) (1)
Medical and Neuro-Oncology (2010) (1)
Accelerated postoperative radiation therapy with weekly concomitant boost in patients with advanced head and neck cancer. (2003) (1)
Malignant Glioma: Viewpoint—Chemotherapy (2015) (1)
Concomitant chemoradiotherapy for solid tumors (1994) (1)
[Angiogenesis inhibition in neurooncology. A very promising therapy strategy for malignant glioma]. (2010) (1)
Clinical, Molecular, and Molecular-Clinical Profile (MCP) Exploratory Subset Analysis of RTOG 0525: a Phase III Trial Comparing Standard (std) Adjuvant Temozolomide (TMZ) with a Dose-dense (dd) Schedule for Glioblastoma (GBM) (2011) (1)
QOLP-11. QUALITY OF LIFE IN HIGH-GRADE GLIOMA PATIENTS ON A PHASE I VIROTHERAPY STUDY (2018) (1)
Extended resection for potentially operable stage III NSCLC patients after neoadjuvant treatment (2022) (1)
P-606 Neoadjuvant chemo- and radiotherapy for stage IIIB non-small cell lung cancer (NSCLC). A prospective multicenter trial by the Swiss group for clinical cancer research (SAKK) (2003) (1)
QOLP-03. MEASURING CHANGE IN HEALTH-RELATED QUALITY OF LIFE: THE ADDED VALUE OF ANALYSIS ON THE INDIVIDUAL PATIENT LEVEL IN GLIOMA PATIENTS IN CLINICAL DECISION MAKING (2019) (1)
Interaction between DNA damage response, translation and apoptosome determines cancer susceptibility to TOP2 poisons (2019) (1)
Calculating the net clinical benefit in neuro-oncology clinical trials using two methods: quality-adjusted survival effect sizes and joint modeling (2020) (1)
The Sixth Lugano Conference: Basic science papers (1997) (1)
P-599 Gefitinib(Iressa) as first-line therapy in advanced non-small lung cancer (2005) (1)
CTNI-31. INTERIM RESULTS OF A PHASE I/IIA STUDY TO EVALUATE THE SAFETY AND EFFICACY OF BBB OPENING WITH THE SONOCLOUD-9 IMPLANTABLE ULTRASOUND DEVICE IN RECURRENT GLIOBLASTOMA PATIENTS PRIOR TO IV CARBOPLATIN (2020) (1)
Preoperative chemoradiotherapy in non-small cell lung cancer (NSCLC) patients with operable stage IIIB disease. A phase II trial of the Swiss Group for Clinical Cancer Research (SAKK) (2007) (1)
Long-term experience with cisplatin-based induction chemotherapy and concomitant chemoradiotherapy in locally advanced head and neck cancer (HNC) (1993) (1)
P-592 Neoadjuvant chemo- and radiotherapy in stage IIIA (N2) non-small cell lung cancer (NSCLC). Rationale for a radomized trial by the swiss group for clinical cancer research (SAKK) (2003) (1)
Preoperative Hyperfractionated Accelerated Radiotherapy (HART) with concomittant CPT-11 immediately followed by surgery and adjuvant chemotherapy. A phase I study (Trial 98-02) (2002) (0)
GLIOBLASTOMA IN ELDERLY PATIENTS: HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN A RANDOMIZED TRIAL COMPARING 6-WEEKS OF TADIOTHERAPY (RT) VS HYPOFRACTIONATED RT OVER 2 WEEKS VS TEMOZOLOMIDE CHEMOTHERAPY (TMZ) in NEURO-ONCOLOGY, vol 12, issue , pp 18-19 (2010) (0)
QOLP-29. SYMPTOM CLUSTERS IN NEWLY DIAGNOSED GLIOMA PATIENTS: WHICH CLUSTERS ARE ASSOCIATED WITH FUNCTIONING AND GLOBAL HEALTH STATUS? (2018) (0)
Avastin and Malignant Gliomas (2010) (0)
Editorial : Questions regarding the optimal use of bevacizumab in glioblastoma : a moving target by (2017) (0)
QLIF-27. THE ADDED VALUE OF HEALTH-RELATED QUALITY OF LIFE (HRQoL) AS A PROGNOSTIC INDICATOR OF OVERALL SURVIVAL AND PROGRESSION FREE SURVIVAL IN GLIOMA PATIENTS: A META-ANALYSIS BASED ON INDIVIDUAL PATIENT DATA FROM RANDOMIZED CONTROLLED TRIALS (2017) (0)
Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment (2023) (0)
P30.01 Extended Resections for Advanced Stages T3/T4 NSCLC After Neoadjuvant Treatment: Conclusions of SAKK Pooled Analysis (16/96, 16/00, 16/01) (2021) (0)
Associations of levetiracetam use with the safety and tolerability profile of chemoradiotherapy for patients with newly diagnosed glioblastoma (2022) (0)
DDEL-10. ULTRASOUND-ENHANCED DRUG DELIVERY IN HUMANS ALTERS ENDOTHELIAL PHENOTYPE AND PERTURBS THE ULTRASTRUCTURE OF THE BLOOD BRAIN BARRIER (2022) (0)
P01.042 Symptom clusters in newly diagnosed glioma patients: which clusters are associated with functioning and global health status? (2018) (0)
116 INVITED Targeted therapies and anti-angiogenic treatments in newly diagnosed malignant glioma (2007) (0)
Abstracts from the 8th Annual Meeting of the Scientific Association of Swiss Radiation Oncology (SASRO) (2004) (0)
Advances in Blood-Brain Barrier Disruption to Facilitate Drug Delivery for Infiltrative Gliomas (2023) (0)
Corrigendum to 'Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials': [ESMO Open Volume 7, Issue 2, (2022), 100455]. (2022) (0)
CTNI-03. A PHASE I/IIA, OPEN-LABEL STUDY OF THE BRAIN-PENETRANT PARP1-SELECTIVE INHIBITOR AZD9574 AS MONOTHERAPY AND IN COMBINATION IN PATIENTS WITH ADVANCED SOLID MALIGNANCIES (CERTIS1) (2022) (0)
[Antineutrophil cytoplasma antibodies (ANCA): clinical indications and experience with these new autoantibodies]. (1991) (0)
DDEL-13. ULTRASOUND-ENHANCED DELIVERY OF LIPOSOMAL DOXORUBICIN ACROSS THE BLOOD BRAIN BARRIER INDUCES AN IFN-GPHENOTYPE IN MICROGLIA, MACROPHAGES, AND T CELLS AND IMPROVES RESPONSE TO PD-1 BLOCKADE IN GLIOMAS (2022) (0)
Chromosome 7 gain and DNA hypermethylation at the HOXA10 locus are associated with expression of a stem cell related HOX-signature in glioblastoma (2015) (0)
IMMU-66. IDO1 EXPRESSION STRATIFIES PATIENT SURVIVAL AND IS REGULATED BY TUMOR INFILTRATING T CELLS IN HUMAN GLIOBLASTOMA (2017) (0)
Combined Treatment for Patients with Brain Metastases from Non-small Cell Lung Cancer with Whole Brain Radiotherapy (WBRT) and Gefitinib (GFT) or Temozolomide (TMZ). A Randomized Multicenter Phase II Trial of the Swiss Group of Clinical Cancer Research (SAKK #70/03) (2010) (0)
Central necrosis of non-small cell lung cancer in 18F-FDG PET: A potential pathognomonic sign for an aggressive disease course (2007) (0)
Treatment of newly diagnosed glioblastoma multiforme [3] (multiple letters) (2002) (0)
Changing Paradigms in the Treatment of Brain Metastases. (2019) (0)
ACTR-57. A PHASE 1/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF BLOOD-BRAIN BARRIER (BBB) OPENING WITH A NINE-EMITTER IMPLANTABLE ULTRASOUND DEVICE IN RECURRENT GLIOBLASTOMA PATIENTS PRIOR TO CARBOPLATIN (2019) (0)
Postoperative 3D conformal radiation therapy with dose-volume histogram assessment in non small-cell lung cancer (2007) (0)
QLIF-25. EFFECT OF TUMOR TREATING FIELDS (TTFIELDS) ON HEALTH-RELATED QUALITY OF LIFE (HRQoL) IN NEWLY DIAGNOSED GLIOBLASTOMA. RESULTS OF THE EF-14 RANDOMIZED PHASE III TRIAL (2017) (0)
Sequential or concomitant chemo- and 3D conformal radiotherapy in limited stage small cell lung cancer: P1-208 (2007) (0)
[Present chemoprevention and future vision]. (2005) (0)
Multimodal treatment in operable stage III non-small cell lung cancer using the new TNM staging classification version 8: Long term results of a pooled analysis of three SAKK trials. (2018) (0)
CENTRIC Trial Results (2013) (0)
P14.25 18F-fluordesoxyglucose positron emission tomography (FDG-PET/CT) the detection of the primary lesion and staging in brain metastasis (BM) patients with cancer of unknown primary site (CUPS) (2016) (0)
P01.032 Associations of anticoagulant use with outcome in newly diagnosed glioblastoma (2018) (0)
Association of antidepressant drug use with outcome of patients with glioblastoma (2022) (0)
TMOD-35. DEVELOPING RECURRENT GBM PDX, IN VIVO, FROM TREATMENT NAÏVE SOURCES (2020) (0)
Abstract B034: Targeting cellular plasticity-driven metabolic adaptation to overcome chemoresistance in GBM (2022) (0)
A phase 1b study of humanized KS-interleukin-2 (huKS-IL2) immunocytokine with cyclophosphamide in patients with EpCAM-positive advanced solid tumors (2013) (0)
Targeted therapies on the horizon for malignant glioma (2010) (0)
Mediast inal Lymph Node Clearance Af ter (2009) (0)
Low-grade astrocytoma, anaplastic oligodendroglioma or astrocytoma, and glioblastoma: The clinical trial portfolio of the EORTC Brain Tumor and Radiation Oncology Groups for newly diagnosed patients. (2010) (0)
24 Molecular profiles of gliomas, mechanistic insights and associations with outcome (2006) (0)
Association of pre-radiotherapy tumor burden and overall survival in newly diagnosed glioblastoma adjusted for MGMT promoter methylation status (2023) (0)
EG-05COMBINATION OF GENE COPY GAIN AND EPIGENETIC DEREGULATION ARE ASSOCIATED WITH THE ABERRANT EXPRESSION OF A STEM CELL RELATED HOX-SIGNATURE IN GLIOBLASTOMA. (2014) (0)
The Sixth Lugano Conference clinical papers: Many remaining questions (1997) (0)
P09.03.A Associations of levetiracetam use with the safety and tolerability of chemoradiotherapy for patients with newly diagnosed glioblastoma (2022) (0)
Modeling Therapy-Driven Evolution of Glioblastoma with Patient-Derived Xenografts (2022) (0)
PCN127 MINIMAL CLINICALLY MEANINGFUL DIFFERENCES FOR THE EORTC QLQ-C30 AND EORTC QLQ-BN20 SCALES IN BRAIN CANCER PATIENTS (2010) (0)
273 INVITED Targeting Angiogenesis in Glioma – Challenges and Pitfalls (2011) (0)
CSIG-18. MODELING TEMOZOLOMIDE RESISTANCE WITH GLIOBLASTOMA PATIENT DERIVED XENOGRAFTS (2018) (0)
Temozolomide does not increase overall survival in recurrent malignant glioma (2002) (0)
Personalized DNA neoantigen vaccine in combination with plasmid IL-12 for the treatment of a patient with anaplastic astrocytoma. (2021) (0)
82 Current status of malignant glioma chemotherapy - hype or hope? (2003) (0)
Molecular pathways in human glioblastoma assessed by gene expression profiling (2001) (0)
BIOM-39. P-ERK ASSOCIATION WITH OVERALL SURVIVAL IN RECURRENT GBM PATIENTS TREATED WITH INTRACEREBRAL ADMINISTRATION OF PD-1 AND CTLA-4 BLOCKING ANTIBODIES (2022) (0)
The impact of boost dose and margins on the local recurrence rate in breast conserving therapy : Results from the EORTC boost-no boost trial (2007) (0)
NEUROCOGNITIVE OUTCOMES OF EORTC BRAIN TUMOR GROUP STUDY 26101 PHASE III TRIAL COMPARING THE COMBINATION OF LOMUSTINE AND BEVACIZUMAB WITH LOMUSTINE ALONE IN GLIOBLASTOMA PATIENTS WITH FIRST PROGRESSION (2017) (0)
EXTH-29. DUAL TGFB AND PD1 BLOCKADE PROMOTES GERMINAL-CENTER B-CELL IMMUNE RESPONSES AGAINST GLIOBLASTOMA (2021) (0)
Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II study (2018) (0)
P3-190: Postoperative 3D Conformal Radiation Therapy in Non Small Cell Lung Cancer (2007) (0)
Online Database Featuring Author , Key Word and Full-Text Search Guidelines on the Management of Low-grade Gliomas : EANO Task Force Report (2018) (0)
TMOD-17. BRAIN TUMOR PATIENT DERIVED XENOGRAFT FROM LUNG TUMOR METASTASIS: ESTABLISHMENT AND CHARACTERIZATION (2017) (0)
Abstract PR011: Targeting cellular plasticity-driven metabolic adaptation to overcome chemoresistance in GBM (2022) (0)
CTNI-20. RESULTS OF A PHASE 1/2 CLINICAL TRIAL OF BLOOD-BRAIN BARRIER (BBB) OPENING WITH THE SONOCLOUD-9 IMPLANTABLE ULTRASOUND DEVICE IN RECURRENT GLIOBLASTOMA PATIENTS RECEIVING IV CARBOPLATIN (2022) (0)
A revised RTOG recursive partitioning analysis (RPA) model for glioblastoma based upon multiplatform biomarker profiles. (2012) (0)
OS05.3.A Temporal muscle thickness as surrogate parameter of sarcopenia in newly diagnosed glioblastoma patients:translational imaging analysis of the CENTRIC EORTC 26071-22072 and CORE trials (2021) (0)
2521 POSTER Quality Assurance in the EORTC Low Grade Glioma Trial 22033–26033: the dummy run (2007) (0)
OS7.4 Calculating the net clinical benefit in brain tumor clinical trials by combining survival and health-related quality of life data using two methods: quality adjusted survival effect sizes (QASES) and joint modelling (JM) (2019) (0)
Central nervous system (2017) (0)
[Gliomas – What I Have to Know in ten Questions]. (2016) (0)
DNA methylation-based age acceleration observed in IDH wild-type glioblastoma is associated with better outcome—including in elderly patients (2022) (0)
Featuring Author , Key Word and Full-Text Search Guidelines on the Management of Low-grade Gliomas : EANO Task Force Report (2016) (0)
BI-12RTOG 0525 RECURSIVE PARTITIONING ANALYSIS BASED ON CLINICAL AND PROTEIN BIOMARKER PARAMETERS (2014) (0)
Predictors of Long Term Survival in Progressive Anaplastic Astrocytoma (2007) (0)
Phase I I S tudy o f C apecitabine a nd O xaliplatin i n F irst- and S econd-Line T reatment o f A dvanced o r M etastatic Colorectal C ancer (2002) (0)
SP-38: The Rational for Concomitant Radio- and Chemotherapy in Malignant Glioma. State of the Art and Future Perspectives (2012) (0)
Factors associated with health-related quality of life (HRQoL) deterioration in glioma patients during the progression-free survival period (2021) (0)
PATH-53. EXPRESSION BASED INTRINSIC GLIOMA SUBTYPES ARE PROGNOSTIC IN LOW GRADE GLIOMAS OF THE EORTC22033-26033 CLINICAL TRIAL. (2017) (0)
Management of lymphoma in the 1990s: introduction to the proceedings of the Fifth International Conference on Malignant Lymphoma. (1994) (0)
EANM Springer Prizes 2009 Awarded (2009) (0)
OS7.2 Measuring change in health-related quality of life: the added value of analysis on the individual patient level in glioma patients in clinical decision making (2019) (0)
OS07.3.A Phase 1/2 clinical trial of blood-brain barrier opening with the SonoCloud-9 implantable ultrasound device in recurrent glioblastoma patients receiving IV carboplatin (2022) (0)
Author Index and Subject Index (2001) (0)
QOLP-04. CALCULATING THE NET CLINICAL BENEFIT IN BRAIN TUMOR TRIALS BY COMBINING SURVIVAL AND HEALTH-RELATED QUALITY OF LIFE DATA USING TWO METHODS: QUALITY ADJUSTED SURVIVAL EFFECT SIZES AND JOINT MODELLING (2019) (0)
Mitotic count is prognostic in IDH-mutant astrocytoma without homozygous deletion of CDKN2A/B. Results of consensus panel review of EORTC trials 26053 and EORTC 22033-26033. (2022) (0)
T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein (2013) (0)
In reply [2] (2007) (0)
AT-43MULTI-CENTRE, RANDOMIZED, DOUBLE-BLIND PHASE II STUDY COMPARING CEDIRANIB (AZD2171) PLUS GEFITINIB (IRESSA, ZD1839) WITH CEDIRANIB PLUS PLACEBO IN SUBJECTS WITH RECURRENT/PROGRESSIVE GLIOBLASTOMA (2014) (0)
Abstract 4031:MGMTmethylation based outcome prediction is associated with two CpG regions separated by a prediction minimum centred at the initiation start site (2012) (0)
IMMU-29. B-CELL-BASED VACCINE PRODUCES GLIOBLASTOMA-REACTIVE ANTIBODIES THAT CONTRIBUTE TO TUMOR CLEARANCE (2021) (0)
Abstract 1122: MST4 phosphorylation of ATG4B regulates autophagic activity, tumorigenicity, and radio resistance in glioblastoma (2018) (0)
EXTH-43. GENERATION OF A B-CELL-BASED VACCINE FOR THE TREATMENT OF GLIOBLASTOMA (2020) (0)
Abstract LB-A01: Molecular subgroup analysis of a randomized trial (EORTC 26082-22081) testing temsirolimus and radiation therapy versus chemoradiotherapy with temozolomide in patients with newly diagnosed glioblastoma without methylation of the MGMT gene promoter (2015) (0)
CMET-11. RESPONSE TO STEREOTACTIC RADIOSURGERY FOR MULTIPLE BRAIN METASTASES BASED ON HISTOLOGY-SPECIFIC SUBTYPE STATUS (2019) (0)
Sixth international conference on malignant lymphoma, June 5-8, 1996, Lugano, Switzerland (1997) (0)
Treatment options in elderly patients with glioblastoma - Authors' reply (2012) (0)
E03: Radiation therapy, chemotherapy and combined chemoradiation in the management of malignant glioma (2007) (0)
NIMG-51. RADIOLOGIC PHENOTYPES ARE TREATMENT SPECIFIC AND ASSOCIATED WITH SURVIVAL - EXPLORATORY ANALYSIS OF EORTC 26101 (2017) (0)
334PDTumor Treating Fields (TTFields) – A novel cancer treatment modality: Translating preclinical evidence and engineering into a survival benefit with delayed decline in quality of life (2017) (0)
114 INVITED Malignant glioma: molecular pathways, mechanisms of disease and resistance to chemoradiotherapy (2007) (0)
C URRENT OPINION Brain metastasis: opportunity for drug development? (2012) (0)
Progress in Neurotherapeutics and Neuropsychopharmacology: Radiotherapy with concurrent and adjuvant temozolomide: a new standard of care for glioblastoma multiforme (2006) (0)
53. Central nervous system (2015) (0)
Chemotherapy in Head and Neck Cancers (2017) (0)
IT-28VACCINATION AGAINST EPIDERMAL GROWTH FACTOR RECEPTOR VARIANT III IN GLIOBLASTOMA: THE RINDOPEPIMUT COMPASSIONATE USE EXPERIENCE (2014) (0)
Integrin for use in the treatment of cancer (2008) (0)
Quality of life (QoL) in SAKK 19/03: A multicenter phase II study of first-line gefitinib followed by chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). Swiss Group for Clinical Cancer Research (SAKK). (2006) (0)
5th International Conference on Malignant Lymphoma--Part I. June 9-12, 1993, Lugano, Switzerland. Selected papers. (1994) (0)
The maturation stage of tumoral tertiary lymphoid structures to predict recurrence risk in localized colorectal cancer. (2017) (0)
101 Accelerated postoperative radiation therapy with weekly concomitant boost in patients with advanced head and neck cancer (2003) (0)
Extended resection for potentially operable patients with stage III non-small cell lung cancer after induction treatment. (2022) (0)
Right Silencing and Stratified Therapy in Glioblastoma (2007) (0)
Letter of Welcome (2012) (0)
TMOD-08. DEVELOPING DERIVATIVE GBM PDX, IN VIVO, FROM TREATMENT NAÏVE SOURCES (2021) (0)
EP-1414: Toxicity of concurrent stereotactic radiotherapy and targeted or immunotherapy: a systematic review (2017) (0)
CART-Cell Therapies inGlioblastoma:AFirst Look (2018) (0)
IMMU-22. COMBINATION IMMUNOTHERAPY WITH IDO1 INHIBITION ENHANCES TREATMENT EFFICACY IN MULTIPLE MODELS OF GLIOBLASTOMA MODEL (2017) (0)
Experiences and views of different key stakeholders on the feasibility of treating cancer-related fatigue (2020) (0)
Cells Increase IDO 1 Expression in GlioblastomaandContribute toDecreasedPatient Survival (2017) (0)
IMMU-07. HUMANIZED BI-SPECIFIC ANTIBODY SHOWS POTENT ACTIVITY IN PATIENT-DERIVED XENOGRAFT MODELS OF GLIOBLASTOMA (2022) (0)
OS5.1 Sequence of bevacizumab and lomustine in patients with first progression of a glioblastoma: phase II EORTC study 26101 (2016) (0)
Radiation therapy and daily concomitant temozolomide in newly diagnosed glioblastoma multiforme: A safe and promising regimen (2000) (0)
EFFECT OF TUMOR TREATING FIELDS (TTFIELDS) ON HEALTH-RELATED QUALITY OF LIFE (HRQoL) IN NEWLY DIAGNOSED GLIOBLASTOMA. RESULTS OF THE EF-14 RANDOMIZED PHASE III TRIAL (2017) (0)
Abstract 2117: The Wnt inhibitory factor 1 (WIF-1) has tumor suppressing functions in glioblastoma potentially by inducing cellular senescence (2011) (0)
BIOM-32. ENDOPLASMIC RETICULUM PROTEIN SSR3 DETERMINES AND PREDICTS RESPONSE TO PACLITAXEL IN BREAST CANCER AND GLIOBLASTOMA (2021) (0)
Comprehensive molecular and immunological analysis to assess the tumor immune contexture in stage II and III colorectal cancer (2016) (0)
(2014). The level of patient-reported outcome reporting in randomised controlled trials of brain tumour patients: A systematic review. Cancer (2018) (0)
Medulloblastomas in adults: lessons from pediatrics (2014) (0)
167 B-cell-based vaccination elicit potent immunity against glioblastoma (2020) (0)
EXTH-52. HARNESSING A B CELL THERAPY TO PROMOTE ANTI-GLIOBLASTOMA HUMORAL RESPONSE (2022) (0)
Abstract P2-16-07: hMMP9 as Predictive Factor for Response and Progression Free Survival in Breast Cancer Patients Treated with Bevacizumab and Pegylated Liposomal Doxorubicin (PLD) (2010) (0)
Prospective study of accerelated postoperative radiation therapy in patients with squamous-cell carcinoma of the head and neck (2003) (0)
P-436 Neoadjuvant chemotherapy followed by pleuropneumonectomy and radiotherapy for pleural mesothelioma: A multicenter phase II trial of the SAKK (2005) (0)
CMET-26. DIAGNOSTIC VALUE OF FDG-PET/CT FOR PATIENTS WITH BRAIN METASTASIS FROM UNKNOWN PRIMARY SITE (2017) (0)
SCIDOT-07. ULTRASOUND DELIVERED ALBUMIN BOUND PACLITAXEL EXTENDS SURVIVAL IN MALIGNANT GLIOMA MODELS AND OUTPERFORMS ULTRASOUND DELIVERED CREMOPHOR PACLITAXEL IN BIO-DISTRIBUTION AND SAFETY (2019) (0)
Characterizing Seizure-Induced Changes in the Glioma Microenvironment. (2021) (0)
P08.01 Tumor cell subpopulation changes during intracranial glioblastoma patient derived xenograft recurrence following radiation, temozolomide, or combination therapy (2017) (0)
[New systemic therapies in oncology]. (2005) (0)
Experiences and views of different key stakeholders on the feasibility of treating cancer-related fatigue (2020) (0)
Malignant Glioma: Chemotherapy Perspective (2008) (0)
Tumor type, epilepsy burden, and seizure documentation: experiences at a single center neuro-oncology clinic. (2021) (0)
395: Epigenetic deregulation of HOXA genes associated with aberrant expression in glioblastoma (2014) (0)
Bevacizumab for Recurrent Glioma - A Personal View (2010) (0)
9206 Long-term follow-up of follicular lymphoma (FL) patients receiving single agent rituximab at two different schedules in trial SAKK 35/98 (2009) (0)
Outcome of stage III Hodgkin's disease. A retrospective analysis after a median follow up of 13 years (1993) (0)
The value of 18F-fluordesoxyglucose positron emission tomography (FDG-PET/CT) in the detection of the primary lesion and for staging in brain metastasis (BM) patients with cancer of unknown primary site (CUPS). (2017) (0)
Clinical trials in neuro-oncology: one step forward, two steps back? (2011) (0)
INNV-13. UNDERSTANDING FACTORS THAT INFLUENCE THE DECISION OF ACCEPTING TUMOR TREATING FIELDS (TTF) THERAPY (2021) (0)
Distant failure remains a major concern in treating locally advanced rectal cancer: Results of preoperative hyperfractionated accelerated radiotherapy (HART) and concomitant CPT-11 (2005) (0)
OS4.6 Does radiation target volume affect health-related quality of life in patients with low grade glioma on the short-term? - a secondary analysis of the EORTC 22033–26033 trial (2018) (0)
GENETIC AND EPIGENETIC DEREGULATION ARE ASSOCIATED WITH THE ABERRANT EXPRESSION OF A STEM CELL RELATED HOX GENE SIGNATURE IN GLIOBLASTOMA (2014) (0)
Recent advances in the medical therapy of high-grade gliomas (2006) (0)
Delivering albumin-bound paclitaxel across the blood-brain barrier for gliomas (2021) (0)
476 Quality assurance report of EORTC 26981/22981 trial on radiotherapy vs radiotherapy and temozolomide for newly diagnosed glioblastoma multiforme: individual case review (2003) (0)
SP-0536: Chemotherapy for recurring glioma/GBM: The optimal treatment techniques (2013) (0)
6546 POSTER Postoperative 3D conformal radiation therapy with dose-volume histogram assessment in non small-cell lung cancer (2007) (0)
Abstract 4927:MGMTpromoter methylation is enriched in glioblastoma derived spheres as compared to respective original tumor tissue and is associated with loss of expression (2010) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Roger Stupp?

Roger Stupp is affiliated with the following schools:

University of Lausanne
Northwestern University
University of Regensburg
Northwestern University
University of Chicago
Aix-Marseille University
University of Bern
University of Miami
University of Zurich